In a developmental neurotoxicity study (MRID [number if available]) [Chemical name (% a.i.)] was administered to [# of animals] female [strain] rats per dose in [by gavage, diet, water, inhalation] at dose levels of 0, x, x, or x  mg/kg bw/day from gestation day [#] through postnatal day [#](Briefly describe study procedures.  Mention all critical and/or unusual procedures, e.g., direct treatment of offspring, neurobehavioral and neuropathology assessments, biochemical measures, etc.)

 

[Concisely describe treatment-related toxicity, at the LOAEL and at doses greater than the LOAEL, for both dams and offspring.  Do not attempt to separate systemic- and developmental-neurotoxicity; it is not possible to make this type of distinction based on the data available in these studies.  If no toxicity was observed, state that there were no treatment-related effects, for maternal animals and/or offspring as appropriate.]

 

The maternal LOAEL is [dose] mg/kg bw/day, based on [endpoint].  The maternal NOAEL is [dose] mg/kg bw/day.

 

The offspring LOAEL is [dose] mg/kg bw/day, based on [endpoint].  The offspring NOAEL is [dose] mg/kg bw/day.

 

[If applicable; list separately for maternal and offspring endpoints when available:]

The LOAEL for plasma cholinesterase inhibition is [dose] mg/kg bw/day, with a NOAEL of [dose] mg/kg bw/day.

The LOAEL for erythrocyte cholinesterase inhibition  is [dose] mg/kg bw/day, with a NOAEL of [dose] mg/kg bw/day.

The LOAEL for brain cholinesterase inhibition is [dose] mg/kg bw/day, with a NOAEL of [dose] mg/kg bw/day.